Search Results - "MAPLES, W. J"

Diagnosis of right atrial metastatic melanoma by transesophageal echocardiographic-guided transvenous biopsy by Malouf, J F, Thompson, R C, Maples, W J, Wolfe, J T

“…Traditionally, tissue diagnosis of malignant melanoma metastatic to the heart necessitated thoracotomy or was done at autopsy. More recently, right or left…”
Get more information

Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin by Edmonson, J H, Hartmann, L C, Long, H J, Colon-Otero, G, Fitch, T R, Jefferies, J A, Braich, T A, Maples, W J

“…In an attempt to learn how best to administer granulocyte-macrophage colony-stimulating factor (GMCSF), the authors performed a Phase I study of this agent…”
Get more information

Colonoscopic red ring sign due to chronic lymphocytic leukemia by Stark, Mark E., Maples, William J., Wolfe, James T., Menke, David M.

Get full text

A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma by CREAGAN, E. T, VEEDER, M. H, SUMAN, V. J, BURCH, P. A, MAPLES, W. J, SCHAEFER, P. L, PFEIFLE, D. M, DALTON, R. J, HATFIELD, A. K, POON, M. A

“…Cimetidine is an H2-receptor antagonist used in the management of peptic ulcer disease and other hypersecretory gastrointestinal disorders. This agent has…”
Get full text

Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma by CREAGAN, E. T, ROWLAND, K. M, SUMAN, V. J, KARDINAL, C. G, MARSCHKE, R. F, MARKS, R. S, MAPLES, W. J

“…Adoptive immunotherapy (AI) with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) is an antineoplastic modality in which immune-activated cells…”
Get full text

Prospective phase I evaluation of radiation therapy, 5-fluorouracil, and levamisole in locally advanced gastrointestinal cancer by Martenson, Jr, J A, Schutt, A J, Grado, G L, Maples, W J, Marschke, Jr, R F

“…A recent clinical trial in patients with resected node-positive colon cancer demonstrated a clear survival advantage for patients treated with adjuvant…”
Get more information

Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma by Merchan, J. R., Pitot, H. C., Qin, R., Liu, G., Fitch, T. R., Maples, W. J., Picus, J., Erlichman, C.

“…Abstract only…”
Get full text

A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas by Attia, S., Mahoney, M. R., Okuno, S. H., Adkins, D., Ahuja, H. G., Ducker, T. P., Maples, W. J., Ochs, L., Wentworth-Hartung, N. L., Erlichman, C., Bailey, H. H.

“…Abstract only…”
Get full text

N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM) by Dronca, R. S., Perez, D. G., Allred, J., Maples, W. J., Creagan, E. T., Pockaj, B. A., Kaur, J. S., Moore, T. D., Marchello, B. T., Markovic, S.

“…Abstract only…”
Get full text

Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients by Merchan, J. R., Pitot, H. C., Qin, R., Liu, G., Fitch, T. R., Picus, J., Maples, W. J., Erlichman, C.

“…Abstract only 5039 Background: Combined mTOR and VEGF blockade is a potentially promising and rational strategy for the treatment of advanced RCC. We…”
Get full text

Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers by Bible, K. C., Smallridge, R. C., Maples, W. J., Molina, J. R., Menefee, M. E., Suman, V. J., Burton, J. K., Bieber, C. C., Ivy, S. P., Erlichman, C.

“…Abstract only 3521 Background: Systemic therapies have had little impact on the outcomes of patients with advanced differentiated thyroid cancers. Methods: A…”
Get full text

Efficacy of PS-341 in combination with paclitaxel (PAC) and carboplatin (CBDCA) for the treatment of metastatic melanoma (MM): A phase II consortium study by Maples, W. J., Suman, V., Croghan, G. A., Albertini, M. R., Linette, G., Flaherty, L. E., Eckardt, J., Amatruda, T., Erlichman, C. E.

“…Abstract only…”
Get full text

Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study by Holen, K. D., Mahoney, M. R., LoConte, N. K., Szydlo, D. W., Picus, J., Maples, W. J., Kim, G. P., Pitot, H. C., Philip, P. A., Thomas, J. P., Erlichman, C. E.

“…Abstract only…”
Get full text

A phase II evaluation of aerosolized GM-CSF (AGM-CSF) plus standard I-MAP/ GM-CSF/MAP/ surgery/ irradiation in the reduction of pulmonary metastases (P-METS) in soft tissue sarcoma (STS) patients (PTS) by Okuno, S. H., Mahoney, M. R., Kabat, B. F., Marks, R. M., Maples, W. J., Fitch, T. J., Petersen, I. A., Beauchamp, C. P., O’ Connor, M. I., Sim, F. H.

“…Abstract only 10058 Background: P-METs remain illusive with standard treatments for STS. AGM-CSF demonstrated tolerability with promising efficacy in reducing…”
Get full text

N0377: Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma by Rao, R. D., Allred, J. B., Windschitl, H. E., Maples, W. J., McWilliams, R. R., Creagan, E. T., Kaur, J. S., Kottchade, L. A., Gornet, M. K., Pockaj, B. A., Markovic, S. N.

“…Abstract only 8530 Background: RAD-001 (Everolimus) is an oral inhibitor of mammalian target of rapamycin (mTOR). Interim analysis results from a phase II…”
Get full text

A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS) by Okuno, S. H., Mahoney, M. R., Bailey, H. H., Adkins, D. R., Maples, W. J., Ettinger, D., Fitch, T. R., Bot, B. M., Erlichman, C. E.

“…Abstract only 9504 Background: CCI-779 inhibits the mammalian target of rapamycin (mTOR), a Ser/Thr kinase involved with the initiation of mRNA translation,…”
Get full text

Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide by Maples, W. J., Stevenson, J., Sumrall, S. V., Naughton, M., Kauh, J., Schwartz, J.

“…Abstract only…”
Get full text

Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide by Maples, W. J., Stevenson, J., Sumrall, S. V., Naughton, M., Kauh, J., Schwartz, J.

“…Abstract only…”
Get full text

Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma by Rao, R. D., Windschitl, H. E., Allred, J. B., Lowe, V. J., Maples, W. J., Gornet, M. K., Suman, V. J., Creagan, E. T., Pitot, H. C., Markovic, S. N.

“…Abstract only 8043 Background: Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that regulates the production vascular endothelial growth…”
Get full text

Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM) by Geyer, S. M., Markovic, S. M., Fitch, T. R., Albertini, M. R., Maples, W. J., Fracasso, P. M., Erlichman, C.

“…Abstract only…”
Get full text